{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T14:38:31Z","timestamp":1773499111182,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dabigatran etexilate (DABE) is a direct oral anticoagulant (DOAC) and may be combined with ticagrelor, a P2Y<jats:sub>12<\/jats:sub> inhibitor with antiplatelet effects. This combination of antiplatelet drugs and anticoagulants would increases the risk of bleeding in patients. In addition, the potential drug interaction may further increase the risk of bleeding. At present, there is scarce research to clarify the results of the interaction between the two. Therefore, we conducted this study to identify the potential impact of ticagrelor on the pharmacokinetics of DABE using physiologically based pharmacokinetic (PBPK) modeling. The models reasonably predicted the concentration-time profiles of dabigatran (DAB), the transformation form after DABE absorption, and ticagrelor. For pharmacokinetic drug-drug interaction (DDI), exposure to DAB at steady state was increased when co-administrated with ticagrelor. The C<jats:sub>max<\/jats:sub> and AUC<jats:sub>0-t<\/jats:sub> of DAB were raised by approximately 8.7% and 7.1%, respectively. Meanwhile, a stable-state ticagrelor co-administration at 400\u2009mg once-daily increased the C<jats:sub>max<\/jats:sub> and AUC<jats:sub>0-t<\/jats:sub> of DAB by approximately 12.8% and 18.8%, respectively. As conclusions, Ticagrelor slightly increased the exposure of DAB. It is possible to safely use ticagrelor in a double or triple antithrombotic regimen containing DABE, only considering the antithrombotic efficacy, but not need to pay much attention on the pharmacokinetic DDI.<\/jats:p>","DOI":"10.1038\/s41598-020-66557-x","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T10:04:43Z","timestamp":1592301883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling"],"prefix":"10.1038","volume":"10","author":[{"given":"Nan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaoqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wensheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"66557_CR1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.amjmed.2017.02.048","volume":"130","author":"CM Gibson","year":"2017","unstructured":"Gibson, C. M. & Finks, S. W. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape? The American journal of medicine 130, 900\u2013906, https:\/\/doi.org\/10.1016\/j.amjmed.2017.02.048 (2017).","journal-title":"The American journal of medicine"},{"key":"66557_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40265-017-0699-z","volume":"77","author":"HA Blair","year":"2017","unstructured":"Blair, H. A. & Keating, G. M. Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation. Drugs 77, 331\u2013344, https:\/\/doi.org\/10.1007\/s40265-017-0699-z (2017).","journal-title":"Drugs"},{"key":"66557_CR3","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s40265-014-0304-7","volume":"74","author":"SL Greig","year":"2014","unstructured":"Greig, S. L. & McKeage, K. Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence. Drugs 74, 1785\u20131800, https:\/\/doi.org\/10.1007\/s40265-014-0304-7 (2014).","journal-title":"Drugs"},{"key":"66557_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2165\/11209080-000000000-00000","volume":"72","author":"CB Burness","year":"2012","unstructured":"Burness, C. B. & McKeage, K. Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs 72, 963\u2013986, https:\/\/doi.org\/10.2165\/11209080-000000000-00000 (2012).","journal-title":"Drugs"},{"key":"66557_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","volume":"47","author":"J Stangier","year":"2008","unstructured":"Stangier, J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clinical pharmacokinetics 47, 285\u2013295, https:\/\/doi.org\/10.2165\/00003088-200847050-00001 (2008).","journal-title":"Clinical pharmacokinetics"},{"key":"66557_CR6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1365-2125.2012.04266.x","volume":"74","author":"PK Chin","year":"2012","unstructured":"Chin, P. K., Vella-Brincat, J. W., Barclay, M. L. & Begg, E. J. Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles? British journal of clinical pharmacology 74, 734\u2013740, https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04266.x (2012).","journal-title":"British journal of clinical pharmacology"},{"key":"66557_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/bcp.12055","volume":"76","author":"X Delavenne","year":"2013","unstructured":"Delavenne, X. et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. British journal of clinical pharmacology 76, 107\u2013113, https:\/\/doi.org\/10.1111\/bcp.12055 (2013).","journal-title":"British journal of clinical pharmacology"},{"key":"66557_CR8","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1055\/s-0034-1381233","volume":"40","author":"G Lippi","year":"2014","unstructured":"Lippi, G., Favaloro, E. J. & Mattiuzzi, C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? Seminars in thrombosis and hemostasis 40, 756\u2013765, https:\/\/doi.org\/10.1055\/s-0034-1381233 (2014).","journal-title":"Seminars in thrombosis and hemostasis"},{"key":"66557_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/fcp.12154","volume":"29","author":"E Ollier","year":"2015","unstructured":"Ollier, E. et al. In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Fundamental & clinical pharmacology 29, 604\u2013614, https:\/\/doi.org\/10.1111\/fcp.12154 (2015).","journal-title":"Fundamental & clinical pharmacology"},{"key":"66557_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.eplepsyres.2016.06.003","volume":"126","author":"C Stollberger","year":"2016","unstructured":"Stollberger, C. & Finsterer, J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy research 126, 98\u2013101, https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.06.003 (2016).","journal-title":"Epilepsy research"},{"key":"66557_CR11","doi-asserted-by":"publisher","unstructured":"Kumar, P. et al. Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic\/Pharmacodynamic Disposition of Dabigatran. Antimicrobial agents and chemotherapy 61, https:\/\/doi.org\/10.1128\/AAC.01201-17 (2017).","DOI":"10.1128\/AAC.01201-17"},{"key":"66557_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00228-016-2115-0","volume":"73","author":"PH Hsyu","year":"2017","unstructured":"Hsyu, P. H., Pignataro, D. S. & Matschke, K. Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. European journal of clinical pharmacology 73, 57\u201363, https:\/\/doi.org\/10.1007\/s00228-016-2115-0 (2017).","journal-title":"European journal of clinical pharmacology"},{"key":"66557_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England journal of medicine 361, 1045\u20131057, https:\/\/doi.org\/10.1056\/NEJMoa0904327 (2009).","journal-title":"The New England journal of medicine"},{"key":"66557_CR14","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","volume":"122","author":"S James","year":"2010","unstructured":"James, S. et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 122, 1056\u20131067, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.933796 (2010).","journal-title":"Circulation"},{"key":"66557_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40256-015-0108-5","volume":"15","author":"S Dhillon","year":"2015","unstructured":"Dhillon, S. Ticagrelor: a review of its use in adults with acute coronary syndromes. American journal of cardiovascular drugs : drugs, devices, and other interventions 15, 51\u201368, https:\/\/doi.org\/10.1007\/s40256-015-0108-5 (2015).","journal-title":"American journal of cardiovascular drugs : drugs, devices, and other interventions"},{"key":"66557_CR16","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40262-015-0290-2","volume":"54","author":"R Teng","year":"2015","unstructured":"Teng, R. Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clinical pharmacokinetics 54, 1125\u20131138, https:\/\/doi.org\/10.1007\/s40262-015-0290-2 (2015).","journal-title":"Clinical pharmacokinetics"},{"key":"66557_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","volume":"27","author":"F Andreotti","year":"2006","unstructured":"Andreotti, F., Testa, L., Biondi-Zoccai, G. G. & Crea, F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. European heart journal 27, 519\u2013526, https:\/\/doi.org\/10.1093\/eurheartj\/ehi485 (2006).","journal-title":"European heart journal"},{"key":"66557_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","volume":"143","author":"MB Rothberg","year":"2005","unstructured":"Rothberg, M. B., Celestin, C., Fiore, L. D., Lawler, E. & Cook, J. R. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Annals of internal medicine 143, 241\u2013250 (2005).","journal-title":"Annals of internal medicine"},{"key":"66557_CR19","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.cjca.2013.04.006","volume":"29","author":"JA Cairns","year":"2013","unstructured":"Cairns, J. A. & McMurtry, M. S. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease. The Canadian journal of cardiology 29, S60\u201370, https:\/\/doi.org\/10.1016\/j.cjca.2013.04.006 (2013).","journal-title":"The Canadian journal of cardiology"},{"key":"66557_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2017.01.001","volume":"40","author":"CA Dezsi","year":"2017","unstructured":"Dezsi, C. A., Dezsi, B. B. & Dezsi, D. A. Antithrombotic treatment in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention. European journal of internal medicine 40, 1\u20137, https:\/\/doi.org\/10.1016\/j.ejim.2017.01.001 (2017).","journal-title":"European journal of internal medicine"},{"key":"66557_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/clc.22572","volume":"39","author":"CP Cannon","year":"2016","unstructured":"Cannon, C. P. et al. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clinical cardiology 39, 555\u2013564, https:\/\/doi.org\/10.1002\/clc.22572 (2016).","journal-title":"Clinical cardiology"},{"key":"66557_CR22","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1111\/jth.12726","volume":"12","author":"S Weisshaar","year":"2014","unstructured":"Weisshaar, S. et al. Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. Journal of thrombosis and haemostasis : JTH 12, 1850\u20131860, https:\/\/doi.org\/10.1111\/jth.12726 (2014).","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"key":"66557_CR23","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon, C. P. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. The New England journal of medicine 377, 1513\u20131524, https:\/\/doi.org\/10.1056\/NEJMoa1708454 (2017).","journal-title":"The New England journal of medicine"},{"key":"66557_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/bph.12533","volume":"171","author":"Y Zhao","year":"2014","unstructured":"Zhao, Y. & Hu, Z. Y. Physiologically based pharmacokinetic modelling and in vivo [I]\/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. British journal of pharmacology 171, 1043\u20131053, https:\/\/doi.org\/10.1111\/bph.12533 (2014).","journal-title":"British journal of pharmacology"},{"key":"66557_CR25","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1124\/dmd.110.032250","volume":"38","author":"R Teng","year":"2010","unstructured":"Teng, R., Oliver, S., Hayes, M. A. & Butler, K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug metabolism and disposition: the biological fate of chemicals 38, 1514\u20131521, https:\/\/doi.org\/10.1124\/dmd.110.032250 (2010).","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"66557_CR26","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","volume":"32","author":"J Oldgren","year":"2011","unstructured":"Oldgren, J. et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European heart journal 32, 2781\u20132789, https:\/\/doi.org\/10.1093\/eurheartj\/ehr113 (2011).","journal-title":"European heart journal"},{"key":"66557_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/MBC.0000000000000406","volume":"27","author":"M Samos","year":"2016","unstructured":"Samos, M. et al. Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 27, 117\u2013120, https:\/\/doi.org\/10.1097\/MBC.0000000000000406 (2016).","journal-title":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis"},{"key":"66557_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.thromres.2014.10.016","volume":"135","author":"OO Braun","year":"2015","unstructured":"Braun, O. O. et al. Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. Thrombosis research 135, 26\u201330, https:\/\/doi.org\/10.1016\/j.thromres.2014.10.016 (2015).","journal-title":"Thrombosis research"},{"key":"66557_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cct.2014.12.002","volume":"40","author":"W Lu","year":"2015","unstructured":"Lu, W. et al. Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. Contemporary clinical trials 40, 166\u2013171, https:\/\/doi.org\/10.1016\/j.cct.2014.12.002 (2015).","journal-title":"Contemporary clinical trials"},{"key":"66557_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cct.2015.05.012","volume":"43","author":"F Gao","year":"2015","unstructured":"Gao, F. et al. Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention. Contemporary clinical trials 43, 129\u2013132, https:\/\/doi.org\/10.1016\/j.cct.2015.05.012 (2015).","journal-title":"Contemporary clinical trials"},{"key":"66557_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ahj.2016.01.004","volume":"174","author":"TJ Povsic","year":"2016","unstructured":"Povsic, T. J. et al. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. American heart journal 174, 120\u2013128, https:\/\/doi.org\/10.1016\/j.ahj.2016.01.004 (2016).","journal-title":"American heart journal"},{"key":"66557_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ejim.2013.01.021","volume":"24","author":"G Di Minno","year":"2013","unstructured":"Di Minno, G., Russolillo, A., Gambacorta, C., Di Minno, A. & Prisco, D. Improving the use of direct oral anticoagulants in atrial fibrillation. European journal of internal medicine 24, 288\u2013294, https:\/\/doi.org\/10.1016\/j.ejim.2013.01.021 (2013).","journal-title":"European journal of internal medicine"},{"key":"66557_CR33","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1007\/s11095-016-1951-z","volume":"33","author":"N Gobeau","year":"2016","unstructured":"Gobeau, N., Stringer, R., De Buck, S., Tuntland, T. & Faller, B. Evaluation of the GastroPlusTM Advanced Compartmental and Transit (ACAT) Model in Early Discovery. Pharmaceutical research 33, 2126\u20132139, https:\/\/doi.org\/10.1007\/s11095-016-1951-z (2016).","journal-title":"Pharmaceutical research"},{"key":"66557_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/psp4.12382","volume":"8","author":"K Doki","year":"2019","unstructured":"Doki, K., Neuhoff, S., Rostami-Hodjegan, A. & Homma, M. Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling. CPT: pharmacometrics & systems pharmacology 8, 118\u2013126, https:\/\/doi.org\/10.1002\/psp4.12382 (2019).","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"key":"66557_CR35","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1016\/j.xphs.2019.03.028","volume":"108","author":"M Zhang","year":"2019","unstructured":"Zhang, M. et al. Prediction of Ticagrelor and its Active Metabolite in Liver Cirrhosis Populations Using a Physiologically Based Pharmacokinetic Model Involving Pharmacodynamics. Journal of pharmaceutical sciences 108, 2781\u20132790, https:\/\/doi.org\/10.1016\/j.xphs.2019.03.028 (2019).","journal-title":"Journal of pharmaceutical sciences"},{"key":"66557_CR36","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00228-013-1543-3","volume":"69","author":"R Teng","year":"2013","unstructured":"Teng, R. & Butler, K. A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. European journal of clinical pharmacology 69, 1801\u20131808, https:\/\/doi.org\/10.1007\/s00228-013-1543-3 (2013).","journal-title":"European journal of clinical pharmacology"},{"key":"66557_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0009-9236(97)90027-8","volume":"62","author":"KS Lown","year":"1997","unstructured":"Lown, K. S. et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clinical pharmacology and therapeutics 62, 248\u2013260, https:\/\/doi.org\/10.1016\/S0009-9236(97)90027-8 (1997).","journal-title":"Clinical pharmacology and therapeutics"},{"key":"66557_CR38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40261-014-0205-2","volume":"34","author":"R Teng","year":"2014","unstructured":"Teng, R., Kujacic, M. & Hsia, J. Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers. Clinical drug investigation 34, 529\u2013536, https:\/\/doi.org\/10.1007\/s40261-014-0205-2 (2014).","journal-title":"Clinical drug investigation"},{"key":"66557_CR39","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1080\/17512433.2017.1370369","volume":"10","author":"C Stollberger","year":"2017","unstructured":"Stollberger, C. Drug interactions with new oral anticoagulants in elderly patients. Expert review of clinical pharmacology 10, 1191\u20131202, https:\/\/doi.org\/10.1080\/17512433.2017.1370369 (2017).","journal-title":"Expert review of clinical pharmacology"},{"key":"66557_CR40","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s13318-017-0434-x","volume":"43","author":"S Hodin","year":"2018","unstructured":"Hodin, S. et al. In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition. European journal of drug metabolism and pharmacokinetics 43, 183\u2013191, https:\/\/doi.org\/10.1007\/s13318-017-0434-x (2018).","journal-title":"European journal of drug metabolism and pharmacokinetics"},{"key":"66557_CR41","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","volume":"389","author":"EM Ohman","year":"2017","unstructured":"Ohman, E. M. et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet 389, 1799\u20131808, https:\/\/doi.org\/10.1016\/S0140-6736(17)30751-1 (2017).","journal-title":"Lancet"},{"key":"66557_CR42","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine 361, 1139\u20131151, https:\/\/doi.org\/10.1056\/NEJMoa0905561 (2009).","journal-title":"The New England journal of medicine"},{"key":"66557_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000352062","volume":"36","author":"W Pfeilschifter","year":"2013","unstructured":"Pfeilschifter, W., Luger, S., Brunkhorst, R., Lindhoff-Last, E. & Foerch, C. The gap between trial data and clinical practice\u2013an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. Cerebrovascular diseases 36, 115\u2013119, https:\/\/doi.org\/10.1159\/000352062 (2013).","journal-title":"Cerebrovascular diseases"},{"key":"66557_CR44","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1160\/TH11-08-0551","volume":"107","author":"S Hartter","year":"2012","unstructured":"Hartter, S., Yamamura, N., Stangier, J., Reilly, P. A. & Clemens, A. Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. Thrombosis and haemostasis 107, 260\u2013269, https:\/\/doi.org\/10.1160\/TH11-08-0551 (2012).","journal-title":"Thrombosis and haemostasis"},{"key":"66557_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2165\/00003088-200645050-00006","volume":"45","author":"HM Jones","year":"2006","unstructured":"Jones, H. M., Parrott, N., Jorga, K. & Lave, T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clinical pharmacokinetics 45, 511\u2013542, https:\/\/doi.org\/10.2165\/00003088-200645050-00006 (2006).","journal-title":"Clinical pharmacokinetics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66557-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66557-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66557-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:18:01Z","timestamp":1670329081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66557-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["66557"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-66557-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"27 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9717"}}